Literature DB >> 28240838

Liver transplantation for patients with alcoholic hepatitis.

Florent Artru1, Alexandre Louvet1, Philippe Mathurin1.   

Abstract

Alcoholic liver disease, considered as a self-inflected disease, is an example of how moral judgment may affect ethical exercise of medicine which requires equity and fair utilization of a scarce resource in a context of organ shortage. Some consider that selection process should prioritize access to liver transplantation (LT) for patients who develop liver failure "through no fault of their own" even if limiting care because of a patient's perceived responsibility has been considered unethical. The absence of improvement after alcohol withdrawal, the high short-term mortality risk and the poor predictability of the 6-month rule in post-LT relapse in alcohol consumption in AH patients not responding to medical therapy led to recommend an evaluation of LT. In the French-Belgian pilot study, 26 patients with severe AH not responding to medical therapy underwent early LT (eLT). Stringent selection criteria were applied. Six-month and 2-year survivals of eLT patients were better than that of non-transplanted matched controls: 77% vs 23% and 71% vs 23% respectively. Alcohol relapse occurred in 12% of patients after eLT. Three studies confirmed these results. The impact organ donation should be limited as showed by a recent survey and the efforts that should be made in public information campaigns based on scientific data and medical ethics. In conclusion, the ongoing accumulation of scientific evidence and requirement of ethical exercise of medicine lead to continue evaluating eLT as a therapeutic option in patients with severe AH not responding to medical therapy.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  alcoholic hepatitis; early liver transplantation; liver transplantation

Mesh:

Year:  2017        PMID: 28240838     DOI: 10.1111/liv.13248

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

1.  Early liver transplant for severe alcoholic hepatitis: establishing a new frontier by ignoring the rule?

Authors:  Julie Zhu; Trana Hussaini; Eric M Yoshida
Journal:  Ann Transl Med       Date:  2018-10

Review 2.  Ethical and allocation issues in liver transplant candidates with alcohol related liver disease.

Authors:  Mai Sedki; Aijaz Ahmed; Aparna Goel
Journal:  Transl Gastroenterol Hepatol       Date:  2022-07-25

Review 3.  Liver transplantation for alcoholic hepatitis: A systematic review with meta-analysis.

Authors:  Astrid Marot; Margaux Dubois; Eric Trépo; Christophe Moreno; Pierre Deltenre
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

4.  Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial.

Authors:  Julie Thompson; Natasha Jones; Ali Al-Khafaji; Shahid Malik; David Reich; Santiago Munoz; Ross MacNicholas; Tarek Hassanein; Lewis Teperman; Lance Stein; Andrés Duarte-Rojo; Raza Malik; Talal Adhami; Sumeet Asrani; Nikunj Shah; Paul Gaglio; Anupama Duddempudi; Brian Borg; Rajiv Jalan; Robert Brown; Heather Patton; Rohit Satoskar; Simona Rossi; Amay Parikh; Ahmed ElSharkawy; Parvez Mantry; Linda Sher; David Wolf; Marquis Hart; Charles Landis; Alan Wigg; Shahid Habib; Geoffrey McCaughan; Steven Colquhoun; Alyssa Henry; Patricia Bedard; Lee Landeen; Michael Millis; Robert Ashley; William Frank; Andrew Henry; Jan Stange; Ram Subramanian
Journal:  Liver Transpl       Date:  2018-03       Impact factor: 5.799

5.  Therapeutic potential of macrophage colony-stimulating factor in chronic liver disease.

Authors:  Sahar Keshvari; Berit Genz; Ngari Teakle; Melanie Caruso; Michelle F Cestari; Omkar L Patkar; Brian W C Tse; Kamil A Sokolowski; Hilmar Ebersbach; Julia Jascur; Kelli P A MacDonald; Gregory Miller; Grant A Ramm; Allison R Pettit; Andrew D Clouston; Elizabeth E Powell; David A Hume; Katharine M Irvine
Journal:  Dis Model Mech       Date:  2022-04-19       Impact factor: 5.732

6.  Patients' Experiences of Life Challenges After Liver Transplantation: A Qualitative Study.

Authors:  Mohammad Taher; Mohssen Nassiri Toossi; Ali Jafarian; Arezoo Rasti; Nahid Dehghan Nayeri
Journal:  J Patient Exp       Date:  2021-02-26

7.  Alox12/15 Deficiency Exacerbates, While Lipoxin A4 Ameliorates Hepatic Inflammation in Murine Alcoholic Hepatitis.

Authors:  Alexander Queck; Annika F Fink; Evelyn Sirait-Fischer; Sabrina Rüschenbaum; Dominique Thomas; Ryan G Snodgrass; Gerd Geisslinger; Hideo A Baba; Jonel Trebicka; Stefan Zeuzem; Andreas Weigert; Christian M Lange; Bernhard Brüne
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.